4.7 Article

Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4

Journal

MOLECULAR ONCOLOGY
Volume 12, Issue 9, Pages 1540-1558

Publisher

WILEY
DOI: 10.1002/1878-0261.12319

Keywords

breast cancer; cytokines; S100A4; tumor microenvironment; tumor-associated macrophages; tumor-stroma interactions

Categories

Funding

  1. Research Council of Norway [222262/F20]
  2. K.G. Jebsen Centre for Breast Cancer Research
  3. Ella and Kristian Nyerrods Legacy
  4. Henrik Homans Minde Legacy
  5. South-Eastern Norway Regional Health Authority [2014061]

Ask authors/readers for more resources

The tumor microenvironment (TME) may influence both cancer progression and therapeutic response. In breast cancer, particularly in the aggressive triple-negative/basal-like subgroup, patient outcome is strongly associated with the tumor's inflammatory profile. Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the TME, shown to be linked to poor prognosis and therapeutic resistance. In this study, we investigated the effect of the metastasis- and inflammation-associated microenvironmental factor S100A4 on breast cancer cells (BCCs) of different subtypes and explored their further interactions with myeloid cells. We demonstrated that extracellular S100A4 activates BCCs, particularly the basal-like subtype, to elevate secretion of pro-inflammatory cytokines. The secreted factors promoted conversion of monocytes to TAM-like cells that exhibited protumorigenic activities: stimulated epithelial-mesenchymal transition, proliferation, chemoresistance, and motility in cancer cells. In conclusion, we have shown that extracellular S100A4 instigates a tumor-supportive microenvironment, involving a network of cytokines and TAM-like cells, which was particularly characteristic for basal-like BCCs and potentiated their aggressive properties. The S100A4-BCC-TAM interaction cascade could be an important contributor to the aggressive behavior of this subtype and should be further explored for therapeutic targeting.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells

Remya Valsalakumari, Sunil Kumar Yadava, Marzena Szwed, Abhilash D. Pandya, Gunhild Mari Maelandsmo, Maria Lyngaas Torgersen, Tore-Geir Iversen, Tore Skotland, Kirsten Sandvig, Jyotsnendu Giri

Summary: The study found that LNCs-PTX were taken up by MDA-MB-468 cells more effectively than the other two cell lines. Additionally, the cytotoxicity of LNCs-PTX on cells was primarily attributed to endocytosis mechanisms involving Cdc42/GRAF-dependent endocytosis and macropinocytosis.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)

Article Chemistry, Multidisciplinary

Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft

Abhilash D. Pandya, Tore-Geir Iversen, Siver Moestue, Maria T. Grinde, Yrr Morch, Sofie Snipstad, Andreas K. O. Aslund, Geir F. Oy, Wanja Kildal, Olav Engebraten, Kirsten Sandvig, Tore Skotland, Gunhild M. Maelandsmo

Summary: PEBCA nanoparticles showed the highest uptake in breast cancer xenografts and lymph nodes, making them the most promising for drug delivery. They also increased infiltration of anti-tumorigenic M1 macrophages in tumors and shifted the M1/M2 macrophage ratio, suggesting potential for modulating immune responses for enhanced therapeutic effects.

NANOMATERIALS (2021)

Article Biochemistry & Molecular Biology

Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model

Mateusz A. Krzyscik, Malgorzata Zakrzewska, Vigdis Sorensen, Geir Frode Oy, Skjalg Brunheim, Ellen M. Haugsten, Gunhild M. Maelandsmo, Antoni Wiedlocha, Jacek Otlewski

Summary: Despite being the second leading cause of death worldwide, cancer still lacks a fully effective therapy, highlighting the urgent need for new targeted anticancer drugs. Researchers have developed novel protein-drug conjugates that successfully inhibit tumor growth in a mouse model of human breast cancer.

BIOMACROMOLECULES (2021)

Article Oncology

EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition

Sigurdur Trausti Karvelsson, Arnar Sigurdsson, Kotryna Seip, Maria Tunset Grinde, Qiong Wang, Freyr Johannsson, Gunhild Mari Maelandsmo, Siver Andreas Moestue, Ottar Rolfsson, Skarphedinn Halldorsson

Summary: The study reveals that the epithelial-to-mesenchymal transition induces metabolic changes in breast epithelial cells, including re-routing of the TCA cycle, increased lipid biosynthesis, and decreased glycolytic rates. The alterations in GSH synthesis modulate the sensitivity of breast epithelial cells to mTOR inhibitors.

MOLECULAR CANCER RESEARCH (2021)

Article Endocrinology & Metabolism

Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer

Caroline E. Nunes-Xavier, Wanja Kildal, Andreas Kleppe, Havard E. Danielsen, Hakon Waehre, Roberto Llarena, Gunhild M. Maelandsmo, Oystein Fodstad, Rafael Pulido, Jose I. Lopez

Summary: This study identified distinct clinical relevance of the two immune checkpoint proteins PD-L1 and B7-H3 in prostate cancer, with B7-H3 potentially serving as a significant therapeutic target.

PROSTATE (2021)

Article Multidisciplinary Sciences

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro

Lisa Svartdal Normann, Miriam Ragle Aure, Suvi-Katri Leivonen, Mads Haugland Haugen, Vesa Hongisto, Vessela N. Kristensen, Gunhild Mari Maelandsmo, Kristine Kleivi Sahlberg

Summary: HER2-positive breast cancer patients that do not respond to targeted treatment have a poor prognosis. Through a high-throughput screen, it was found that certain miRNA mimics can sensitize HER2+ breast cancer cells to targeted therapy, with miR-101-5p showing a correlation with better prognosis in patients. This suggests the potential of combining targeted drugs with miRNAs to improve current treatments for HER2+ breast cancers.

SCIENTIFIC REPORTS (2021)

Article Oncology

Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer

Vegar Johansen Dagenborg, Serena Elizabeth Marshall, Krzysztof Grzyb, Asmund Avdem Fretland, Marius Lund-Iversen, Gunhild Mari Maelandsmo, Anne Hansen Ree, Bjorn Edwin, Sheraz Yaqub, Kjersti Flatmark

Summary: The study found a significant accumulation of T-cells in the IM regions of both pCRC and CLM, with lower densities in the IT regions. The correlation between T-cell densities in pCRC and matched CLM was poor for all regions and subtypes. The ratios of TH : CTL and Treg : TH were different between pCRC and CLM, indicating a potential immune suppressive microenvironment in both types of tumors.

FRONTIERS IN ONCOLOGY (2021)

Article Mathematical & Computational Biology

Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer

Sigurdur Trausti Karvelsson, Qiong Wang, Bylgja Hilmarsdottir, Arnar Sigurdsson, Siver Andreas Moestue, Gunhild Mari Maelandsmo, Skarphedinn Halldorsson, Steinn Gudmundsson, Ottar Rolfsson

Summary: Proteomic data provides more accurate predictions of metabolic fluxes compared to transcriptomic data when describing breast epithelial metabolism in the context of EMT. The altered cholesterol metabolism and increased dependency on argininosuccinate lyase (ASL) following EMT predicted by proteomic GSMMs were confirmed through drug assays and siRNA knockdown experiments. The iBreast2886 metabolic reconstruction model can be utilized to interpret high throughput clinical data and identify subtype-specific vulnerabilities in breast cancer patients.

NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2021)

Meeting Abstract Oncology

B7-H3 immune checkpoint protein expression is associated with immune exhaustion, overall survival and metastasis in clear cell renal cell carcinoma

C. E. Nunes-Xavier, M. Emaldi, T. Oyjord, G. Larrinaga, P. Errarte, J. C. Angulo, R. Llarena, G. M. Maelandsmo, O. Fodstad, R. Pulido, J. I. Lopez

ANNALS OF ONCOLOGY (2021)

Article Multidisciplinary Sciences

AXL inhibition improves BRAF-targeted treatment in melanoma

Marta Nyakas, Karianne Giller Fleten, Mads Haugland Haugen, Nikolai Engedal, Christina Sveen, Inger Nina Farstad, Vivi Ann Florenes, Lina Prasmickaite, Gunhild Mari Maelandsmo, Kotryna Seip

Summary: This study investigated the therapeutic potential of combining an AXL inhibitor (AXLi) and a clinically relevant BRAF inhibitor (BRAFi) for the treatment of metastatic melanoma. The results showed that AXL was expressed in the majority of melanoma lymph node metastases. In vitro experiments demonstrated that the combination of AXLi and BRAFi resulted in the largest reduction in cell viability. Moreover, pre-clinical studies using AXL(high) melanoma models showed a therapeutic benefit of adding AXLi to the BRAF-targeted therapy. Mechanistic insights revealed that AXLi potentiated BRAFi-induced apoptosis, stimulated ferroptosis, and inhibited autophagy. Overall, this study suggests that combining AXLi with standard therapy could improve the therapeutic outcome in metastatic melanoma.

SCIENTIFIC REPORTS (2022)

Article Oncology

Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer

Caroline E. Nunes-Xavier, Janire Mingo, Maite Emaldi, Karine Flem-Karlsen, Gunhild M. Maelandsmo, Oystein Fodstad, Roberto Llarena, Jose I. Lopez, Rafael Pulido

Summary: This study revealed heterogeneous expression of PDH complex components in PCa tumors, with PDH complex components being related to AR signaling and PDK2 expression associated with poor PCa prognosis. These findings highlight the potential of targeting PDH complex components for intervention in PCa.

FRONTIERS IN ONCOLOGY (2022)

Article Multidisciplinary Sciences

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer

Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N. N. Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Maelandsmo

PLOS ONE (2023)

Article Oncology

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

Vigdis Nygaard, Anne Hansen Ree, Vegar Johansen Dagenborg, Anne-Lise Borresen-Dale, Bjorn Edwin, Asmund Avdem Fretland, Krzysztof Grzyb, Mads H. Haugen, Gunhild M. Maelandsmo, Kjersti Flatmark

Summary: A mesenchymal subgroup with an immunosuppressive phenotype, characterized by high expression of immune checkpoints HAVCR2/TIM-3 and VISTA, as well as the M2 macrophage marker CD163, was identified in colorectal cancer liver metastases. These findings suggest potential novel opportunities for immune-based therapy approaches in microsatellite stable colorectal cancer.

CANCER RESEARCH COMMUNICATIONS (2023)

Article Oncology

ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series

Margherita Ambrosini, Marzia Del Re, Paolo Manca, Andrew Hendifar, Alexander Drilon, Guilherme Harada, Anne Hansen Ree, Samuel Klempner, Gunhild Mari Maelandsmo, Kjersti Flatmark, Hege G. Russnes, James M. Cleary, Harshabad Singh, Elisa Sottotetti, Antonia Martinetti, Giovanni Randon, Andrea Sartore-Bianchi, Iolanda Capone, Massimo Milione, Maria Di Bartolomeo, Filippo Pietrantonio

Summary: This study collected data from patients with GI cancers and ALK rearrangements, showing remarkable responses and clinical benefit with ALK inhibitors. Despite the low frequency, ALK rearrangements play an important role in personalized treatment for GI cancers.

JCO PRECISION ONCOLOGY (2022)

Article Oncology

PPM1D activity promotes the replication stress caused by cyclin E1 overexpression

Andra S. Martinikova, Miroslav Stoyanov, Anna Oravetzova, Yannick P. Kok, Shibo Yu, Jana Dobrovolna, Pavel Janscak, Marcel van Vugt, Libor Macurek

Summary: Oncogene-induced replication stress is a major cause of genome instability in cancer cells. This study reveals that increased activity of PPM1D exacerbates replication stress caused by cyclin E1 overexpression, leading to abnormal cell cycle progression and accumulation of DNA copy number alterations. Pharmacological inhibition of PPM1D can alleviate replication stress-induced genome instability.

MOLECULAR ONCOLOGY (2024)

Article Oncology

ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway

Alamelu G. Bharadwaj, Meghan E. McLean, Margaret L. Dahn, Hannah F. Cahill, Marie-Claire D. Wasson, Raj Pranap Arun, Olivia L. Walker, Brianne M. Cruickshank, Wasundara Fernando, Jaganathan Venkatesh, Penelope J. Barnes, Gillian Bethune, Gregory Knapp, Lucy K. Helyer, Carman A. Giacomantonio, David M. Waisman, Paola Marcato

Summary: ALDH1A3 regulates the plasminogen activation pathway to promote breast cancer metastasis. Co-expression of ALDH1A3 and tPA is associated with TNBC subtype, high tumor grade, and recurrent metastatic disease.

MOLECULAR ONCOLOGY (2024)

Article Oncology

Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression

Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.

MOLECULAR ONCOLOGY (2024)

Article Oncology

Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread

Nuria Gendrau-Sanclemente, Agnes Figueras, Kristina Gracova, Alvaro Lahiguera, Elisenda Alsina-Sanchis, Juan A. Marin-Jimenez, August Vidal, Xavier Matias-Guiu, Sergi Fernandez-Gonzalez, Marc Barahona, Lola Marti, Jordi Ponce, Francesc Vinals

Summary: High-grade serous ovarian cancer (HGSOC), the deadliest gynecological malignancy, spreads through transcoelomic dissemination. This study reveals that platelet-derived growth factor receptor beta (PDGFRβ) is essential for the formation of tumorspheres in HGSOC. Inhibition of PDGFRβ blocks the clustering of ovarian cancer cells and prevents peritoneal dissemination.

MOLECULAR ONCOLOGY (2024)